DOCSLIB.ORG

Active Versus Passive Vaccination: Advantages and Disadvantages Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ACTIVE vs PASSIVE IMMUNIZATION: ADVANTAGES AND DISADVANTAGES OF EACH APPROACH Arturo Casadevall Albert Einstein College of Medicine Bronx, New York DEFINITIONS • ACTIVE IMMUNIZATION = VACCINES • PASSIVE IMMUNIZATION = PREFORMED ANTIBODY ADMINISTRATION ACTIVE IMMUNIZATION - VACCINES ADVANTAGES DISADVANTAGES • LONG PROTECTION • DEPENDENT ON HOST • LESS COSTLY (TO ADMINISTER) IMMUNE SYSTEM – NOT EVERYONE MAY BE PROTECTED • PROTECTIVE RESPONSE TAKES TIME • MAY BE IMPRACTICAL FOR NOSOCOMIAL INFECTION • LONG DEVELOPMENT TIME • ? EFFECTS ON MICROFLORA PASSIVE IMMUNIZATION ADVANTAGES DISADVANTAGES • IMMEDIATE IMMUNITY • COSTLY • PHARMACOLOGIC CONTROL • TEMPORARY IMMUNITY • RAPID DEVELOPMENT TIME • REQUIRES IV ADMINISTRATION • DOSE-RESPONSE UNCERTAINTY REAGENTS FOR PASSIVE THERAPY: mAbs ADVANTAGES DISADVANTAGES • HIGH SPECIFIC ACTIVITY • COST • PRECISE PHARMACOLOGIC • SINGLE SPECIFITY DEFINITION – SELECTION FOR ESCAPE MUTANTS – EFFECTIVENESS α 1/ANTIGENIC • SINGLE ISOTYPE DIVERSITY • LOT TO LOT CONSTANCY • SINGLE ISOTYPE – LIMITED EFFECTOR FUNCTION – LIMITED FcR ENGAGEMENT REAGENTS FOR PASSIVE THERAPY: POLYCLONAL SERA ADVANTAGES DISADVANTAGES • MULTIPLE SPECIFICITIES • LOW SPECIFIC ACTIVITY • MULTIPLE ISOTYPES • LOT TO LOT VARIATION • REQUIREMENT FOR IMMUNIZED DONORS • COST • CONCERN ABOUT INADVERTENT TRANSMISSION OF DISEASE NEW INSIGHTS INTO ANTIBODY-MEDIATED PROTECTION FROM STUDIES WITH A FUNGAL PATHOGEN Or 20 years of work in 18 minutes C. NEOFORMANS – ONLY ENCAPSULATED EUKARYOTIC PATHOGEN OF HUMANS CAPSULE IS THE MAJOR VIRULENCE FACTOR POLYSACCHARIDE CAPSULE ? GLUCURONOXYLOMANNAN MAJOR VIRULENCE FACTOR WEILER HOSPITAL, NEW YORK CITY SUMMER 1988 30-SOMETHING CAMBODIAN MAN WITH C. NEOFORMANS MENINGITIS DIES AGONIZING DEATH DESPITE RECEIVING LARGE DOSES OF AMPHOTERICIN B DURING A PERIOD OF 3 MONTHS… COULD ANTIBODY THERAPY BE DEVELOPED? CIRCA 1990 ADVICE • WORK ON RELEVANT IMMUNOLOGY – CELL MEDIATED IMMUNITY • IF YOU WANT A SCIENTIFIC CAREER DON’T WORK ON USEFUL THINGS •GET A DIFFERENT PROJECT – YOU ARE GOING TO DISCOVER WHAT WE KNOW ABOUT PNEUMOCOCCUS IMMUNOLOGICALTHE GREAT IMMUNOLOGICAL PARADIGMS CATASTROPHE 1970-1990s 1891-1910 1910-1940 1940-1960s HUMORAL IMMUNITY HUMORAL IMMUNITY VIRUSES VIRUSES TOXINS TOXINS ENCAPSULATED BACTERIA ENCAPSULATED BACTERIA “T CELLS ARE USEFUL ONLY FOR STIMULATING B CELLS” HUMORAL ANTIBODY Th2 VS PROTECTS PHAGOCYTIC AGAINST THEORIES ALL MICROBES Th1 ‘TISSUE’ IMMUNITY CELLULAR IMMUNITY MYCOBACTERIA MYCOBACTERIA FUNGI FUNGI INTRACELLULAR PATHOGENS INTRACELLULAR PATHOGENS FOUR ‘HUMORAL “ANTIBODIES ARE USEFUL ONLY IN ELISAs” ‘HUMORS’ IMMUNITY GALEN METHODS FOR ESTABLISHING USEFULNESS OF ANTIBODY-MEDIATED PROTECTION 1. PASSIVE TRANSFER EXPERIMENTS (1891) IMMUNE SERA + INFECTIOUS PROTECTION? SUSCEPTIBLE HOST CHALLENGE LOGICAL ERROR: 2. CORRELATEJUST ANTIBODY BECAUSE THE TITER ASSAY WITH SUGGESTED RESISTANCE THAT (1900s)ANTIBODY WAS NOT SUSCEPTIBILITY 1/titerPROTECTIVE DID NOT MEAN THAT ANTIBODY COULD 3. ASSOCIATE SUSCEPTIBILITY WITHNOT BE ANTIBODY PROTECTIVE DEFICIT (1940s) ERROR INVOLVED MAKING A POSITIVE INFERENCE FROM PROBLEM: THESE METHODSNEGATIVE SUGGEST DATA SPECIFIC ANTIBODY IS NOT IMPORTANT IN DEFENSE AGAINST MANY PATHOGENS e.g. Mycobacterium tuberculosis Cryptococcus neoformans Listeria monocytogenes Many others…. PROBLEM: EXPERIMENTS WITH POLYCLONAL SERA ARE INCONCLUSIVE A DIFFERENT APPROACH TT IMMUNIZE GXM MAKE Y Y Y Y Y 100 mAbs IgG2a 80 60 40 PROTECTION STUDIES of Survival % 20 0 0 20 40 60 80 100 120 140 160 Days NON-PROTECTIVE mAb PROTECTIVE mAb YYYYYY YYYYYY NON-PROTECTIVE mAbs INHIBITED EFFICACY OF PROTECTIVE mAbs ANTIBODY-MEDIATED PROTECTION AGAINST M. TUBERCULOSIS CONTROL CONFIRMATION (5 independent labs): PETHE ET AL. NATURE 2001:412;190 HAMASUR ET AL. VACCINE 2003:20:4081 WILLIAMS ET AL. IMMUNOLOGY 2004:111;328 CHAMBERS ET AL. FEMS IMMUNOL.MED.MICROBIOL. 2004:41;93 PROC.NATL.ACAD.SCI 1998:95;15688 HAMESURE ET AL. CLIN.EXP.IMMUNOLmAb 9d8 2005: 138:30-8 THE CMI vs. HUMORAL PARADIGM UNTENABLE PROTECTIVE MAbs MADE TO: HUMORAL IMMUNITY VIRUSES CRYPTOCOCCUS NEOFORMANS (FUNGUS) TOXINS ENCAPSULATED BACTERIA CANDIDA ALBICANS (FUNGUS) LISTERIA MONOCYTOGENES (INTRACELLULAR BACTERIA) HISTOPLASMA CAPSULATUM (INTRACELLULAR FUNGUS) MYCOBACTERIUM TUBERCULOSIS (INTRACELLULAR BACTERIA) NEW APPROACH USE MAbs EHRLICHIA CHAFFENSIS (INTRACELLULAR BACTERIA) LEISHMANIA MEXICANA (INTRACELLULAR PARASITE) CELLULAR IMMUNITY MYCOBACTERIA FUNGI TWO EMERGING EXPLANATIONS SOME BACTERIA VIRUSES ‘GOOD & BAD’ INADEQUATE AMOUNTS TOXINS (SUPERANTIGENS) C. neoformans L. monocytogenes C. albicans H. capsulatum M. tuberculosis WHY IS IT SO HARD TO PROTECT AGAINST SOME MICROBES WITH ANTIBODY? THE THINGS THAT MATTER…. • SPECIFICITY • ISOTYPE • AMOUNT IgM IgG • DEPENDENCE ON HOST PROTECTIVE NON- PROTECTIVE NON- PROTECTIVE PROTECTIVE CELL-MEDIATED IMMUNITY PATTERN ANNULAR PUNCTATE ANNULAR ANNULAR GENETICS OPSONIC YES NO YES YES INHIBITS YES NO YES YES PS RELEASE ISOTYPE NA NA IgG1, IgG2a, IgG3 IgG2b NEED C3 YES NO NO NO TWO STORIES: IgM – EFFICACY REQUIRES ‘RIGHT’ SPECIFICITY AND COMPLEMENT IgG - EFFICACY REQUIRES ‘RIGHT’ ISOTYPE AND HOST WHAT IS THE DIFFERENCE BETWEEN PROTECTIVE AND NON- PROTECTIVE ANTIBODIES? PARENTAL mAb 12A1 B CELL mAb 13F1 9F11 IgG1 7G7 IgM 4G9 IgG1 16E4 PROTECTIVE IgM NON-PROTECTIVE 12A1 15E8 IgM IgM 12F4 IgG1 14E1 13F1 IgG1 IgM CLINICAL 18B7 25G12 IgA TRIAL IgG1 USED BY VH7183 JH2 BALB/c 7 aa D NZB/NZW Casadevall & Scharff J Exp Med. 1991;174(1):151-60 C3H/He Mukherjee et al J Exp Med. 1993;177(4):1105-16 HUMAN USE V 3 Mukherjee et al J Exp Med. 1995 Jan 1;181(1):405-9 H Nussbaum et al J Exp Med. 1997 Feb 17;185(4):685-94. Vk5.1 Jk1 POSITIONS 33 AND 57 IN PROTECTIVEAND NON-PROTECTIVE CLASS II MAbS TO C. NEOFORMANS POLYSACCHARIDE mAb 33 57 PROTECTIVE IF 3B10 F N YES ANNULAR 2D10 F R YES ANNULAR 2H1 F K YES ANNULAR 3E5 F N YES ANNULAR 18G9 F K YES ANNULAR 10F10 F S YES ANNULAR 12A1 F N YES ANNULAR 17E12 F K YES ANNULAR 18B7 F K YES ANNULAR 471 L K YES ANNULAR 3C2 L K YES ANNULAR 13F1 Y S NO PUNCTATE 21D2 Y S NO PUNCTATE ANTIBODY BINDING SITE FROM X-RAY CRYSTAL STRUCTURE 12A1 N Y F M S W V M I N I N G N N T Y Y P D T V K G D R D G T F G N Y Y A M ANNULAR S31N S - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ANNULAR F33Y - - Y - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ANNULAR M50A - - - - - - - A - - - - - - - - - - - - - - - - - - - - - - - - - - - - ANNULAR I53S - - - - - - - - - - S - - - - - - - - - - - - - - - - - - - - - - - - - ANNULAR D56G - - - - - - - - - - - - - G - - - - - - - - - - - - - - - - - - - - - - ANNULAR N57S - - - - - - - - - - - - - - S - - - - - - - - - - - - - - - - - - - - - ANNULAR D80Y - - - - - - - - - - - - - - - - - - - - - - - - Y - - - - - - - - - - - ANNULAR TYROSINE PHENYLALANINE G103Y - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Y - - - - - - ANNULAR F33Y,N57S - - Y - - - - - - - - - - - S - - - - - - - - - - - - - - - - - - - - - PUNCTATE 13F1 S - Y - - - - A - - - - - G S - - - - - - - - - Y - - - - Y - - - - - - PUNCTATE Young et al. J. Mol.Biol. 1997 Nakouzi et al Infect Immun. 2001;69(5):3398-409 COMPLEMENT-INDEPENDENT IgM-MEDIATED PHAGOCYTOSIS OF C. NEOFORMANS CD18 BINDING SITE mAb 13F1 mAb 12A1 CR3 CR3 MACROPHAGE Taborda et al. Immunity 2002 PROTECTIVE AND NON-PROTECTIVE IgM mAbs MEDIATE C3 LOCALIZATION IN DIFFERENT PARTS OF CAPSULE LIGHT IgM C3 MERGE FUNGAL CELLS IN VIVO COATED WITH COMPLEMENT IS DEPOSITED IgM IN ‘PUNCTATE PATTERN IN VIVO AWAY FROM SURFACE PROTECTIVE Ce NON- PROTECTIVE Zaragoza et al. Eur. J. Immunol 2003 Zaragoza et al Infect Immun 2004 Zaragoza et al. Cell Micro 2006 C. neoformans BIOFILM FORMATION 2 h 4 h 8 h 1.6 1.4 B3501 24067 1.2 H99 I23 1 S. cerevisiae C. albicans 50 µm 0.8 OD 492 nm OD 492 0.6 0.4 0.2 0 2 4 8 24 48 Time (h) 16 h 24 h 48 h Adhesion Microcolony Maturation 5 µm PROTECTIVE ANTIBODIES BLOCK BIOFILM FORMATION No Ab MAb 18B7 MAb 3671 (control) 50 µm 50 µg/ml 50 µg/ml BCIP Y Vectastain Y Biotin-GAM-IgM 2D10 100 µg/ml 100 µg/ml 1.6 B3501 1.4 100 24067 B3501 H99 1.2 80 1 60 C. neoformans C. p<0.05 0.8 40 OD 492 nm OD 492 0.6 biofilmsmetabolic activity 20 * Percentage of Percentage * 0.4 0 No Ab 50 100 50 100 50 100 50 100 ug/ml ug/ml ug/ml ug/ml ug/ml ug/ml ug/ml ug/ml 0.2 12A1 12A1 13F1 13F1 21D2 21D2 5C11 5C11 0 PROTECTIVE NON-PROTECTIVE IRRELEVANT No Ab 50 ug/ml 18B7 100 ug/ml 18B7 50 ug/ml 3671 100 ug/ml 3671 Exopolymeric matrix No Ab Y Ab Y Y Ab cross-links Y Y Biofilm Y capsule Interference with Y biofilm formation HOW DOES ANTIBODY INTERFERE WITH FUNGAL PHYSIOLOGY? IgG AND C3 OPSONIZATION HAVE DIFFERENT OUTCOMES IN EXIT DISPERSION IgG OPSONIZATION C3 OPSONIZATION ANTIBODY BINDING CAN ALTER MICROBIAL GENE EXPRESSION PROTECTIVE IgG1 PROTECTIVE IgM NON-PROTECTIVE IgM RELATIVE TO RELATIVE TO RELATIVE TO IRRELEVANT CONTROL IRRELEVANT CONTROL IRRELEVANT CONTROL McClelland, Nicola, Prados, Casadevall J. Clin Invest 2010 JANOFF & FRANK, JCI 2010 (IN PRESS) COMMENTARY MTb RESPONSE UPON CAPSULAR MAB TREATMENT Mid-log phase H37Rv defined MM culture 10 mg/ml Mab 45 min Expression ratio: Capsular Mab/isotype IgG MORE IS NOT BETTER: PROZONE-LIKE EFFECTS 100 90 80 70 60 50 40 70 30 0.05 20 PercentSurvival 10 0.1 60 0 0.2 Culture (ml) 50 0.4 0.2 0.1 0.4 0.05 0.025 40 0.0125 0.00625 0.00156 30 0.003125 Horse Immune Sera (ml) 20 Average Survival (d) Survival Average 3 10 10 PNEUMOCOCCUS 1935 4 10 5 0 10 Innoculum7 A SINGLE mAb CAN BE PROTECTIVE, 1 6 0.5 10 0.1 NON-PROTECTIVE OR DISEASE control mAb 12A1 (mg/mouse) ENHANCING DEPENDING ON ITS CONCENTRATION AND INOCULUM C. NEOFORMANS
Recommended publications

  • IFM Innate Immunity Infographic

    UNDERSTANDING INNATE IMMUNITY INTRODUCTION The immune system is comprised of two arms that work together to protect the body – the innate and adaptive immune systems. INNATE ADAPTIVE γδ T Cell Dendritic B Cell Cell Macrophage Antibodies Natural Killer Lymphocites Neutrophil T Cell CD4+ CD8+ T Cell T Cell TIME 6 hours 12 hours 1 week INNATE IMMUNITY ADAPTIVE IMMUNITY Innate immunity is the body’s first The adaptive, or acquired, immune line of immunological response system is activated when the innate and reacts quickly to anything that immune system is not able to fully should not be present. address a threat, but responses are slow, taking up to a week to fully respond. Pathogen evades the innate Dendritic immune system T Cell Cell Through antigen Pathogen presentation, the dendritic cell informs T cells of the pathogen, which informs Macrophage B cells B Cell B cells create antibodies against the pathogen Macrophages engulf and destroy Antibodies label invading pathogens pathogens for destruction Scientists estimate innate immunity comprises approximately: The adaptive immune system develops of the immune memory of pathogen exposures, so that 80% system B and T cells can respond quickly to eliminate repeat invaders. IMMUNE SYSTEM AND DISEASE If the immune system consistently under-responds or over-responds, serious diseases can result. CANCER INFLAMMATION Innate system is TOO ACTIVE Innate system NOT ACTIVE ENOUGH Cancers grow and spread when tumor Certain diseases trigger the innate cells evade detection by the immune immune system to unnecessarily system. The innate immune system is respond and cause excessive inflammation. responsible for detecting cancer cells and This type of chronic inflammation is signaling to the adaptive immune system associated with autoimmune and for the destruction of the cancer cells.
  • Discussion of Natural Killer Cells and Innate Immunity

    Discussion of Natural Killer Cells and Innate Immunity

    Discussion of natural killer cells and innate immunity Theresa L. Whiteside, Ph.D. University of Pittsburgh Cancer Institute Pittsburgh, PA 15213 Myths in tumor immunology • Cancer cells are ignored by the immune system • Immune responses are directed only against “unique” antigens expressed on tumor cells • Tumor-specific T cells alone are sufficient for tumor regression • Tumor are passive targets for anti-tumor responses Tumor/Immune Cells Interactions Tumor cell death C G DC M TUMOR NK Th B Tc Ab Ag Ag/Ab complex NK cells as anti-tumor effectors • LGL, no TCR, express FcγRIII, other activating receptors and KIRs • Spare normal cells but kill a broad range of tumor cells ex vivo by at least two different mechanisms • Produce a number of cytokines (IFN-γ, TNF-α) • Constitutively express IL-2Rβγ and rapidly respond to IL-2 and also to IL-15 and IFNα/β • Regulated by a balance of inhibitory receptors specific for MHC class I antigens and activating signals • NK-DC interactions at sites of inflammation Heterogeneity of human NK cells • Every NK cell expresses at least one KIR that recognizes a self MHC class I molecule • Two functionally distinct subsets: 1) 90% CD56dimCD16bright , highly cytotoxic, abundant KIR expression, few cytokines 2) 10% CD56brightCD16dim/neg, produce cytokines, poorly cytotoxic, low KIR expression Expression of activating and inhibitory receptors on NK cells Interaction with CD56 Interaction with MHC ligands non-MHC ligands KIR CD16 CD2 CD94/NKG2A/B β2 NKp46, 44, 30 CD94/NKG2C/E NK Cell 2B4 NKG2D Lair1 LIR/ILT A
  • COVID-19 Natural Immunity

    COVID-19 Natural Immunity

    COVID-19 natural immunity Scientific brief 10 May 2021 Key Messages: • Within 4 weeks following infection, 90-99% of individuals infected with the SARS-CoV-2 virus develop detectable neutralizing antibodies. • The strength and duration of the immune responses to SARS-CoV-2 are not completely understood and currently available data suggests that it varies by age and the severity of symptoms. Available scientific data suggests that in most people immune responses remain robust and protective against reinfection for at least 6-8 months after infection (the longest follow up with strong scientific evidence is currently approximately 8 months). • Some variant SARS-CoV-2 viruses with key changes in the spike protein have a reduced susceptibility to neutralization by antibodies in the blood. While neutralizing antibodies mainly target the spike protein, cellular immunity elicited by natural infection also target other viral proteins, which tend to be more conserved across variants than the spike protein. The ability of emerging virus variants (variants of interest and variants of concern) to evade immune responses is under investigation by researchers around the world. • There are many available serologic assays that measure the antibody response to SARS-CoV-2 infection, but at the present time, the correlates of protection are not well understood. Objective of the scientific brief This scientific brief replaces the WHO Scientific Brief entitled “’Immunity passports’ in the context of COVID-19”, published 24 April 2020.1 This update is focused on what is currently understood about SARS-CoV-2 immunity from natural infection. More information about considerations on vaccine certificates or “passports”will be covered in an update of WHO interim guidance, as requested by the COVID-19 emergency committee.2 Methods A rapid review on the subject was undertaken and scientific journals were regularly screened for articles on COVID-19 immunity to ensure to include all large and robust studies available in the literature at the time of writing.
  • Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP)

    Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP)

    Morbidity and Mortality Weekly Report Recommendations and Reports February 8, 2002 / Vol. 51 / No. RR-2 General Recommendations on Immunization Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP) INSIDE: Continuing Education Examination Centers for Disease Control and Prevention SAFER • HEALTHIER • PEOPLETM MMWR CONTENTS The MMWR series of publications is published by the Introduction ......................................................................... 1 Epidemiology Program Office, Centers for Disease Timing and Spacing of Immunobiologics .............................. 2 General Principles for Vaccine Scheduling ......................... 2 Control and Prevention (CDC), U.S. Department of Spacing of Multiple Doses of the Same Antigen ................ 2 Health and Human Services, Atlanta, GA 30333. Simultaneous Administration ............................................ 4 Nonsimultaneous Administration ...................................... 5 Spacing of Antibody-Containing Products and Vaccines ..... 6 SUGGESTED CITATION Interchangeability of Vaccines from Different Manufacturers 8 Centers for Disease Control and Prevention. General Lapsed Vaccination Schedule ............................................ 8 recommendations on immunization: recom- Unknown or Uncertain Vaccination Status ......................... 8 mendations of the Advisory Committee on Contraindications and Precautions ....................................... 8 Immunization Practices and the
  • Prospecting for an HIV Vaccine D

    Prospecting for an HIV Vaccine D

    Brett-Major et al. Tropical Diseases, Travel Medicine and Vaccines (2017) 3:6 DOI 10.1186/s40794-017-0050-4 REVIEW Open Access Prospecting for an HIV vaccine D. M. Brett-Major1,2*, T. A. Crowell1,2 and N. L. Michael1 Abstract Human immunodeficiency virus (HIV) sets several challenges for the development of a preventative HIV vaccine. Predictable, protective natural immunity against HIV does not occur and so unlike most other diseases for which vaccines exist, there are few guideposts from natural infection. Nonetheless, six vaccine efficacy trials have occurred. One in particular, the Thai trial called RV144, showed partial protective efficacy and potential ways ahead to a better vaccine approach. This coupled with other lessons from studies of acute infections as well as an increasingly complex knowledge of HIV-related vaccine immunology bring hope that a vaccine solution might be reached for this pervasive and deadly pandemic. Keywords: Human immunodeficiency virus vaccine protective efficacy immunology review Background Why not already Human immunodeficiency virus (HIV) disease remains A reasonable person new to the global conversation one of the greatest threats to global public health. about HIV might ask, if an HIV vaccine is so critical and According to the World Health Organization (WHO), in the pandemic known for three decades, why do we not 2014 over one million people died from HIV, nearly already have an HIV vaccine? There is no simple answer thirty-seven million people had chronic infection and to this question, though an easy one is that people do two million people newly acquired infections [1]. Of not develop natural, protective immunity to HIV infec- those persons known to be HIV infected, only 35% tion and disease.
  • The Model of “Informed Refusal” for Vaccination: How to Fight Against Anti-Vaccinationist Misinformation Without Disregarding the Principle of Self-Determination

    The Model of “Informed Refusal” for Vaccination: How to Fight Against Anti-Vaccinationist Misinformation Without Disregarding the Principle of Self-Determination

    Communication The Model of “Informed Refusal” for Vaccination: How to Fight against Anti-Vaccinationist Misinformation without Disregarding the Principle of Self-Determination Stefano D’Errico 1, Emanuela Turillazzi 2, Martina Zanon 1, Rocco Valerio Viola 3, Paola Frati 3,4 and Vittorio Fineschi 3,4,* 1 Department of Surgery, Medicine and Health, University of Trieste, 34149 Trieste, Italy; [email protected] (S.D.); [email protected] (M.Z.) 2 Department of Surgical Pathology, Medical, Molecular and Critical Area, Institute of Legal Medicine, University of Pisa, 56126 Pisa, Italy; [email protected] 3 Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University of Rome, Viale Regina Elena 336, 00161 Rome, Italy; [email protected] (R.V.V.); [email protected] (P.F.) 4 IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico) Neuromed Mediterranean Neurological Institute, Via Atinense 18, 86077 Pozzilli, Italy * Correspondence: [email protected]; Tel.: +39 06 49912722 Abstract: Vaccines are arguably a public health success story as well as an incredibly cost-effective medical resource. Despite this, worldwide concerns about their safety are growing, with the risk of Citation: D’Errico, S.; Turillazzi, E.; increased morbidity and mortality in vaccine-preventable diseases because of vaccine refusal. The Zanon, M.; Viola, R.V.; Frati, P.; global political trend in developed countries is to increasingly reduce mandates and the compulsory Fineschi, V. The Model of “Informed nature of vaccination programs. This is due to strong opposition from anti-vaccination movements Refusal” For Vaccination: How to and groups. While these have existed since the beginnings of vaccinology, they have recently gained Fight Against Anti-Vaccinationist a strong foothold through massive exploitation of the media and especially the internet.
  • Innate Immunity and Inflammation

    Innate Immunity and Inflammation

    ISBTc ‐ Primer on Tumor Immunology and Biological Therapy of Cancer InnateInnate ImmunityImmunity andand InflammationInflammation WillemWillem Overwijk,Overwijk, Ph.D.Ph.D. MDMD AndersonAnderson CancerCancer CenterCenter CenterCenter forfor CancerCancer ImmunologyImmunology ResearchResearch Houston,Houston, TXTX www.allthingsbeautiful.com InnateInnate ImmunityImmunity andand InflammationInflammation • Definitions • Cells and Molecules • Innate Immunity and Inflammation in Cancer • Bad Inflammation • Good Inflammation • Therapeutic Implications InnateInnate ImmunityImmunity andand InflammationInflammation • Definitions • Cells and Molecules • Innate Immunity and Inflammation in Cancer • Bad Inflammation • Good Inflammation • Therapeutic Implications • Innate Immunity: Immunity that is naturally present and is not due to prior sensitization to an antigen; generally nonspecific. It is in contrast to acquired/adaptive immunity. Adapted from Merriam‐Webster Medical Dictionary • Innate Immunity: Immunity that is naturally present and is not due to prior sensitization to an antigen; generally nonspecific. It is in contrast to acquired/adaptive immunity. • Inflammation: a local response to tissue injury – Rubor (redness) – Calor (heat) – Dolor (pain) – Tumor (swelling) Adapted from Merriam‐Webster Medical Dictionary ““InnateInnate ImmunityImmunity”” andand ““InflammationInflammation”” areare vaguevague termsterms •• SpecificSpecific cellcell typestypes andand moleculesmolecules orchestrateorchestrate specificspecific typestypes ofof inflammationinflammation
  • Understanding the Immune System: How It Works

    Understanding the Immune System: How It Works

    Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute NIH Publication No. 03-5423 September 2003 www.niaid.nih.gov www.nci.nih.gov Contents 1 Introduction 2 Self and Nonself 3 The Structure of the Immune System 7 Immune Cells and Their Products 19 Mounting an Immune Response 24 Immunity: Natural and Acquired 28 Disorders of the Immune System 34 Immunology and Transplants 36 Immunity and Cancer 39 The Immune System and the Nervous System 40 Frontiers in Immunology 45 Summary 47 Glossary Introduction he immune system is a network of Tcells, tissues*, and organs that work together to defend the body against attacks by “foreign” invaders. These are primarily microbes (germs)—tiny, infection-causing Bacteria: organisms such as bacteria, viruses, streptococci parasites, and fungi. Because the human body provides an ideal environment for many microbes, they try to break in. It is the immune system’s job to keep them out or, failing that, to seek out and destroy them. Virus: When the immune system hits the wrong herpes virus target or is crippled, however, it can unleash a torrent of diseases, including allergy, arthritis, or AIDS. The immune system is amazingly complex. It can recognize and remember millions of Parasite: different enemies, and it can produce schistosome secretions and cells to match up with and wipe out each one of them.
  • (ACIP) General Best Guidance for Immunization

    (ACIP) General Best Guidance for Immunization

    Appendix 1: Glossary Adverse event. An undesirable medical condition that occurs following vaccination which might be truly caused by a vaccine, or it might be pure coincidence. Adverse reaction. An undesirable medical condition that has been demonstrated to be caused by a vaccine. Evidence for the causal relation is usually obtained through randomized clinical trials, controlled epidemiologic studies, isolation of the vaccine strain from the pathogenic site, or recurrence of the condition with repeated vaccination (i.e., rechallenge); synonyms include side effect and adverse effect. Adjuvant. A vaccine component distinct from the antigen that enhances the immune response to the antigen. Antitoxin. A solution of antibodies against a toxin. Antitoxin can be derived from either human (e.g., tetanus immune globulin) or animal (usually equine) sources (e.g., diphtheria and botulism antitoxin). Antitoxins are used to confer passive immunity and for treatment. Hyperimmune globulin (specific). Special preparations obtained from blood plasma from donor pools preselected for a high antibody content against a specific antigen (e.g., hepatitis B immune globulin, varicella-zoster immune globulin, rabies immune globulin, tetanus immune globulin, vaccinia immune globulin, cytomegalovirus immune globulin, botulism immune globulin). Immune globulin. A sterile solution containing antibodies, which are usually obtained from human blood. It is obtained by cold ethanol fractionation of large pools of blood plasma and contains 15%-18% protein. Intended for intramuscular administration, immune globulin is primarily indicated for routine maintenance of immunity among certain immunodeficient persons and for passive protection against measles and hepatitis A. General Best Practice Guidelines for Immunization: Appendix 1: Glossary 189 Immunobiologic. Antigenic substances (e.g., vaccines and toxoids) or antibody- containing preparations (e.g., globulins and antitoxins) from human or animal donors.
  • A Role of Inflammation and Immunity in Essential Hypertension—Modeled and Analyzed Using Petri Nets

    A Role of Inflammation and Immunity in Essential Hypertension—Modeled and Analyzed Using Petri Nets

    International Journal of Molecular Sciences Article A Role of Inflammation and Immunity in Essential Hypertension—Modeled and Analyzed Using Petri Nets Dorota Formanowicz 1 , Agnieszka Rybarczyk 2,3 , Marcin Radom 2,3 and Piotr Formanowicz 2,3,* 1 Department of Clinical Biochemistry and Laboratory Medicine, Poznan University of Medical Sciences, 60-806 Poznan, Poland; [email protected] 2 Institute of Computing Science, Poznan University of Technology, 60-965 Poznan, Poland; [email protected] (A.R.); [email protected] (M.R.) 3 Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland * Correspondence: [email protected] Received: 15 April 2020; Accepted: 5 May 2020; Published: 9 May 2020 Abstract: Recent studies have shown that the innate and adaptive immune system, together with low-grade inflammation, may play an important role in essential hypertension. In this work, to verify the importance of selected factors for the development of essential hypertension, we created a Petri net-based model and analyzed it. The analysis was based mainly on t-invariants, knockouts of selected fragments of the net and its simulations. The blockade of the renin-angiotensin (RAA) system revealed that the most significant effect on the emergence of essential hypertension has RAA activation. This blockade affects: (1) the formation of angiotensin II, (2) inflammatory process (by influencing C-reactive protein (CRP)), (3) the initiation of blood coagulation, (4) bradykinin generation via the kallikrein-kinin system, (5) activation of lymphocytes in hypertension, (6) the participation of TNF alpha in the activation of the acute phase response, and (7) activation of NADPH oxidase—a key enzyme of oxidative stress.
  • COVID-19: About Vaccines This Guidance Provides Basic Information Only

    COVID-19: About Vaccines This Guidance Provides Basic Information Only

    COVID-19: About Vaccines This guidance provides basic information only. It is not intended to take the place of medical advice, diagnosis or treatment, legal advice or legal requirements. • Please check the Government of New Brunswick’s COVID-19 website regularly for updates to this document. list of symptoms, other guidance documents, Directives and other information. COVID-19 Vaccines: Overview Representing a turning point in our fight against COVID-19, Health Canada has authorized the Pfizer-BioNTech mRNA vaccine. More vaccines will likely be authorized in the near future.1 What you should know: • Health Canada only approves a vaccine if it is supported by very robust scientific data and evidence. • After approval, Health Canada and the Public Health Agency of Canada continue to monitor the ongoing safety and effectiveness of all approved vaccines. • Canadians will have easy access to detailed information on the vaccine and the evidence behind the vaccine approval process through the Government of Canada's website. • The benefits of vaccination greatly outweigh the risks, and many more illnesses and deaths would occur without vaccines. Vaccines prevent illness and disease and save lives and livelihoods. Mass vaccination will protect people's lives and help Canada recover from the COVID-19 pandemic. After more than a decade of research and development on mRNA vaccines, this vaccine is the first mRNA vaccine approved for use in humans. To date, mRNA has been successfully used in cancer treatments, and research into its value for vaccinations has been ongoing for over ten years. 1 Soon after original publication of this document, Health Canada authorized the Moderna mRNA vaccine.
  • Vaccine Immunology Claire-Anne Siegrist

    Vaccine Immunology Claire-Anne Siegrist

    2 Vaccine Immunology Claire-Anne Siegrist To generate vaccine-mediated protection is a complex chal- non–antigen-specifc responses possibly leading to allergy, lenge. Currently available vaccines have largely been devel- autoimmunity, or even premature death—are being raised. oped empirically, with little or no understanding of how they Certain “off-targets effects” of vaccines have also been recog- activate the immune system. Their early protective effcacy is nized and call for studies to quantify their impact and identify primarily conferred by the induction of antigen-specifc anti- the mechanisms at play. The objective of this chapter is to bodies (Box 2.1). However, there is more to antibody- extract from the complex and rapidly evolving feld of immu- mediated protection than the peak of vaccine-induced nology the main concepts that are useful to better address antibody titers. The quality of such antibodies (e.g., their these important questions. avidity, specifcity, or neutralizing capacity) has been identi- fed as a determining factor in effcacy. Long-term protection HOW DO VACCINES MEDIATE PROTECTION? requires the persistence of vaccine antibodies above protective thresholds and/or the maintenance of immune memory cells Vaccines protect by inducing effector mechanisms (cells or capable of rapid and effective reactivation with subsequent molecules) capable of rapidly controlling replicating patho- microbial exposure. The determinants of immune memory gens or inactivating their toxic components. Vaccine-induced induction, as well as the relative contribution of persisting immune effectors (Table 2.1) are essentially antibodies— antibodies and of immune memory to protection against spe- produced by B lymphocytes—capable of binding specifcally cifc diseases, are essential parameters of long-term vaccine to a toxin or a pathogen.2 Other potential effectors are cyto- effcacy.